BS Ajaikumar, founder and executive chairman of specialty cancer care chain HealthCare Global Enterprises (HCG), on Wednesday launched a thematic healthcare and life sciences fund with an initial corpus of $20 million ('166 crore).While the oncologist-turned-entrepreneur contributed 90% of the corpus for the Inviga Healthcare Fund, the remaining 10% is from Equirus Capital founder and managing director Ajay Garg.The fund will invest up to '40 crore in equity and provide strategic expertise to early-stage and mid-level companies of Indian clinicians, scientists and entrepreneurs, Ajaikumar said.'Through the Inviga Health Fund, we will support Indian doctors, scientists and healthcare entrepreneurs, to help them grow professionally and reach their potential by addressing funding or operational issues that may be preventing this,' Ajaikumar told ET.On Wednesday, it announced its first investment of $2 million in Mynvax, a biotech startup focused on developing novel recombinant vaccines for human respiratory viral diseases, including seasonal influenza and Covid-19.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

专业癌症护理连锁医疗保健全球企业（HCG）创始人兼执行主席BS Ajaikumar周三启动了一个主题医疗保健和生命科学基金，初始资金为2000万美元（合1.66亿美元）。这位肿瘤学家出身的企业家为因维加医疗基金贡献了90%的资金，其余10%来自Equirus Capital创始人兼董事总经理阿杰伊·加格（AjayGarg）。阿贾伊·库马尔表示，该基金将向股权投资高达4000万卢比，并为印度临床医生、科学家和企业家的早期和中期公司提供战略专业知识阿贾伊·库马尔（Ajaikumar）周三告诉ET，我们将通过因维加健康基金（Inviga Health Fund）支持印度医生、科学家和医疗保健企业家，通过解决可能阻止这种情况的资金或运营问题，帮助他们专业成长并发挥其潜力。该基金宣布首次向Mynvax投资200万美元。Mynvax是一家生物技术初创公司，专注于开发针对人类呼吸道病毒疾病（包括季节性流感和新型冠状病毒）的新型重组疫苗。（您现在可以订阅我们的经济时报WhatsApp频道）（您现在可以订阅我们的经济时报WhatsApp频道）。